Over time, pharmaceutical
players have demonstrated significant interest in this domain and have launched
clinical research initiatives to investigate the relevance and applications of
these novel biomarkers. Several companies have already developed / are
developing analytical tests for novel cancer biomarkers (TMB, MSI / MMR and
TILs), intended to assist physicians in making personalized treatment decisions.
To order this 370+ page report, which features 190+ figures
and 180+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html
The USD 860 million (by 2030) financial opportunity within the
cancer biomarkers market has been analyzed across the following segments:
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
The Cancer
Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019–2030.”
report features the
following companies, which we identified to be key players in this domain:
§
§
§
§
§
§
§
Table of Contents
1. Preface
4. Current Market Landscape
5. Product Competitiveness Analysis
6. Company Profiles
7. Publication Analysis
8. Innovative Designs for Biomarker-Based Clinical Trials
9. Clinical Trial Analysis
10. Market Forecast
11. Future Growth Opportunities
12. Case Study: Analysis of Needs of Stakeholders in
The Companion Diagnostics Industry
13. Case Study: Analysis of Value Chain in the Companion
Diagnostics Industry
14. Clinical Research on Cancer Biomarkers: A Big Pharma
Perspective
15. Executive Insights
16. Appendix 1: Tabulated Data
17. Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com